Brief: Thalia Therapeutics To Buy Sanmirna Therapeutics For Clinical-Stage AML RNA Therapy
24/06/2026 07:51
BRIEF-Thalia Therapeutics To Buy Sanmirna Therapeutics For Clinical-Stage AML RNA Therapy June 24 (Reuters) - Thalia Therapeutics PLC THAT.L:
THALIA THERAPEUTICS - ACQUISITION AND £2.75 MILLION FUNDRAISE
THALIA THERAPEUTICS - TO BUY SANMIRNA THERAPEUTICS FOR CLINICAL-STAGE AML RNA THERAPY
THALIA THERAPEUTICS - DEAL VALUE £3.68 MILLION INITIAL, UP TO £13 MILLION DEFERRED MILESTONES
Source text: ID:nRSX5447Ja
Further company coverage: THAT.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Thalia Therapeutics
See all newsThalia Therapeutics - Interim Results
Brief: Thalia Therapeutics Says New Patent Granted For Miristen In China
Thalia Therapeutics - New Patent Granted for miRisten in China
Thalia Therapeutics - RNA gene-silencing cardiovascular program advances
Thalia Therapeutics - Business Update and Notice of Results